New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
domperidone, domperidona, domperidonum
Class :
Anti-emetic agents, Prokinetic agents
Brand Name :
No Data Available.
Synonyms :
domperidone, domperidona, domperidonum
Class :
Anti-emetic agents, Prokinetic agents
Dosage forms & Strengths
Tablet
10mg
Oral suspension
10ml
Suppository
30mg
Indicated for Dopamine-agonist Anti-Parkinson agents linked to nausea and vomiting
10 mg orally 3 times daily
Do not increase the daily dose to more than 30 mg/day
Dosage forms & Strengths
Tablet
10mg
Oral suspension
10ml
Suppository
30mg
For children >12 years
10 mg orally 3 times daily
Do not increase the daily dose to more than 30 mg/day
Indicated for Dopamine-agonist Anti-Parkinson agents linked to nausea and vomiting
For children >12 years
10 mg orally 3 times daily
Do not increase the daily dose to more than 30 mg/day
Refer to the adult dosing
may enhance the Qtc prolonging effect
may enhance the Qtc prolonging effect
may enhance the Qtc prolonging effect
may enhance the Qtc prolonging effect
may enhance the Qtc prolonging effect
may have an increased QTc-prolonging effect when combined with domperidone
may have an increased QTc-prolonging effect when combined with domperidone
may have an increased QTc-prolonging effect when combined with domperidone
may have an increased QTc-prolonging effect when combined with domperidone
may increase the QTc-prolonging effect of QT-prolonging Agents
they increase the concentration of domperidone in serum
it increases the concentration of CYP3A4 substrates in serum
QT-prolonging CYP3A4 substrates increase the QTc prolonging effect of ketoconazole
it increases the effect of QT-prolonging agents
may have an increased QTc-prolonging effect when combined with domperidone
may have an increased QTc-prolonging effect when combined with domperidone
may have an increased QTc-prolonging effect when combined with domperidone
may have an increased QTc-prolonging effect when combined with domperidone
may enhance the concentration of serum when combined with domperidone
may enhance the concentration of serum when combined with domperidone
may enhance the concentration of serum when combined with domperidone
may enhance the concentration of serum when combined with domperidone
may enhance the concentration of serum when combined with domperidone
domperidone: they may enhance the serum concentration of CYP3A Inhibitors
domperidone: they may enhance the serum concentration of CYP3A Inhibitors
domperidone: they may enhance the serum concentration of CYP3A Inhibitors
domperidone: they may enhance the serum concentration of CYP3A Inhibitors
domperidone: they may enhance the serum concentration of CYP3A Inhibitors
may increase the QT-prolonging effect
QT-prolonging agents increase the QTc prolonging effect of domperidone
may enhance the serum concentration
they decrease the effect of gastrointestinal agents
domperidone decreases the effect of bromocriptine
it increases the concentration of CYP3A4 substrates
prokinetic GI agents decrease the concentration of fosfomycin in serum
they increase the toxic effect of domperidone
they decrease the effect of prokinetic GI agents
prokinetic GI agents decrease the concentration of sirolimus in serum
when ajmaline is used together with domperidone, the risk or seriousness of QTc prolongation is enhanced
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
when bromazepam and domperidone are used together, there is a potential reduction in the bromazepam's metabolism
It may enhance the risk of adverse effects when combined with dopamine receptors antagonists
It may enhance the risk of adverse effects when combined with dopamine receptors antagonists
It may enhance the risk of adverse effects when combined with dopamine receptors antagonists
When domperidone is used together with somatotropin, this leads to a rise in domperidone metabolism
When domperidone is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When domperidone is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
When indisulam is used together with domperidone, this leads to a reduction in domperidone metabolism
domperidone: it may decrease the metabolism of gestodene
it may increase the QT-c prolonging effect of QT-prolonging agents such as toremifene
may increase the QTc prolonging effect of QT-prolonging agents
spironolactone and hydrochlorothiazide
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
When domeperidone and acalabrutinib is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and acebutolol is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and acetaminophen is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and acyclovir is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and adagrasib is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and alfentanil is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and almotriptan is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and alosetron is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and alpelisib is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and alprazolam is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and amiodarone is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and amphetamine is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and amprenavir is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and aprepitant is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and asunaprevir is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and atazanavir is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and atenolol is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and atorvastatin is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and azathioprine is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and azelastine is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and benzocaine is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and benzphetamine is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and betaxolol is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and bexarotene is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and bosutinib is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and bupivacaine is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and buprenorphine is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and bupropion is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and buspirone is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and cabozantinib is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and caffeine is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and cannabidiol is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and capsaicin is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and carmustine is used together, this leads to reduction in the domeperidone’s metabolism
When domeperidone and celecoxib is used together, this leads to reduction in the domeperidone’s metabolism
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
When domperidone is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
it increases the QTc-prolonging effect of domperidone
domperidone increases the QTc prolongation of ondansetron
they increase the QTc prolongation of QT-prolonging agents
QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of domperidone
QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of domperidone
QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of domperidone
QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of domperidone
it increases the QTc prolongation effect of ondansetron
Actions and Spectrum:
Frequency defined
1-10%
Headache
Xerostomia
<1%
Acid regurgitation
Hot flash
Dysuria
Dizziness
Heartburn
Stomatitis
Contraindication/Caution
Pregnancy consideration:
Studies show limited usage of domperidone in pregnant females
Breastfeeding warnings:
domperidone is known for its excretion in breastmilk.
Pregnancy category:
Pharmacology:
domperidone is a dopamine antagonist that acts on the dopamine receptors in the gastrointestinal tract and the chemoreceptor trigger zone in the brain. It has both prokinetic and antiemetic effects.
domperidone works by blocking the dopamine D2 receptor, which inhibits the release of acetylcholine and increases the release of dopamine in the gastrointestinal tract. This results in an increase in gastrointestinal motility and a reduction in nausea and vomiting.
Pharmacodynamics:
The main pharmacodynamic effects of domperidone are:
Pharmacokinetics:
The pharmacokinetics of domperidone include:
Absorption
domperidone is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 30-60 minutes.
Distribution
domperidone is widely distributed throughout the body and has a high volume of distribution.
Metabolism
domperidone is metabolized in the liver by the cytochrome P450 system, primarily by CYP3A4.
Elimination and Excretion
domperidone is primarily eliminated in the urine and feces, with a half-life of approximately 7 hours.
Administration:
domperidone is typically administered orally and is available in tablet, suspension, and suppository forms. The recommended dose of domperidone may vary depending on the condition being treated and the patient’s individual response to the medication. It is important to follow the dosing instructions provided by your healthcare provider.
The usual adult dose of domperidone for the treatment of gastrointestinal motility disorders is 10-20 mg three to four times daily before meals and at bedtime. The maximum daily dose should not exceed 80 mg. For the treatment of nausea and vomiting, the usual adult dose is 10 mg three to four times daily. The maximum daily dose should not exceed 30 mg.
domperidone is not recommended for use in children under the age of 12 years old, as safety and effectiveness in this population have not been established. domperidone should be taken 15-30 minutes before meals and at bedtime, as food can interfere with its absorption. It is important to swallow the tablets whole and not crush or chew them.
Patient information leaflet
Generic Name: domperidone
Pronounced: dom-peri-done
Why do we use domperidone?
domperidone is used for the treatment of gastrointestinal motility disorders and nausea and vomiting. Specifically, it is used to treat conditions such as:
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
